OncoMatch/Clinical Trials/NCT04513808
Total Intravenous Anesthesia and Recurrence Free Survival
Is NCT04513808 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Propofol-based total intravenous anesthesia and Sevoflurane intravenous anesthesia for esophageal cancer.
Treatment: Propofol-based total intravenous anesthesia · Sevoflurane intravenous anesthesia — The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Performance status
ASA 0–3
Demographics
Prior therapy
Cannot have received: surgery
Exception: diagnostic biopsies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04513808 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages